Echocardiographic assessment of the structural and functional state of the heart and the cardioprotective effects of mesenchymal stem cell conditioned medium in combined doxorubicin and celecoxib cardiotoxicity
Article Sidebar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Main Article Content
https://orcid.org/0009-0003-4753-7366
Abstract
The aim – to perform an echocardiographic assessment of structural and functional cardiac alterations in combined doxorubicin- and celecoxib-induced cardiomyopathy and to determine the cardioprotective efficacy of mesenchymal stem cell-conditioned medium.
Materials and methods. The study was conducted in 28 rats with experimentally induced doxorubicin- and celecoxib-associated cardiomyopathy. Echocardiographic evaluation of left ventricular morphometric, volumetric, and functional parameters was performed. The cardioprotective effects of mesenchymal stem cell–conditioned medium were compared with those of carvedilol using parametric and nonparametric statistical analyses.
Results and discussion. Combined doxorubicin and celecoxib exposure resulted in marked left ventricular dilatation, with a 27.7 % increase in end-diastolic volume (p=0.049) and a 194.5 % increase in end-systolic volume (p<0.001) compared with intact animals. Myocardial mass increased by 11.9 % (p=0.002), while fractional shortening and ejection fraction decreased by 51.3 % and 41.2 %, respectively (p<0.001). Carvedilol reduced end-systolic volume by 56.9 % and increased fractional shortening by 90.7 % (p<0.001). Mesenchymal stem cell-conditioned medium provided a more profound correction, reducing end-diastolic volume by 22.1 % (p=0.004) and end-systolic volume by 60.1 % (p<0.001), normalizing end-diastolic diameter, and increasing interventricular septal systolic thickening by 109.5 % (p=0.028).
Conclusions. The combined cardiotoxic effects of doxorubicin and celecoxib induce severe dilatational and systolic cardiac remodeling. Mesenchymal stem cell-conditioned medium exerts a robust cardioprotective effect, surpassing carvedilol in the depth of echocardiographic normalization and restoration of myocardial contractile function.
Article Details
Keywords:
References
Bhutani V, Varzideh F, Wilson S, Kansakar U, Jankauskas SS, Santulli G. Doxorubicin-induced cardiotoxicity: a comprehensive update. J Cardiovasc Development and Disease. 2025;12(6):207. https://doi.org/10.3390/jcdd12060207
Oliveira MS, Melo MB, Carvalho JL, Melo IM, Lavor MS, Gomes DA, de Goes AM, Melo MM. Doxorubicin cardiotoxicity and cardiac function improvement after stem cell therapy diagnosed by strain echocardiography. Journal of Cancer Science & Therapy. 2013;5(2):52-7. https://doi.org/10.4172/1948-5956.1000184
Zhang J, Li X, Liu J, Shang Y, Tan L, Guo Y. Early and dynamic detection of doxorubicin-induced cardiotoxicity by myocardial contrast echocardiography combined with two-dimensional speckle tracking echocardiography in rats. Frontiers in Cardiovasc Med. 2023;9:1063499. https://doi.org/10.3389/fcvm.2022.1063499
Haesen S, Steegen L, Deluyker D, Bito V. Comprehensive transthoracic echocardiographic evaluation of doxorubicin-induced cardiotoxicity: a multimodal imaging approach in an animal model. Eur Heart J – Imaging Methods and Practice. 2025;3(1):qyaf006. https://doi.org/10.1093/ehjimp/qyaf006
Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy. 2021;139:111708. https://doi.org/10.1016/j.biopha.2021.111708
Hladkykh FV, Liadova TI, Komorovskyi RR, Chyzh MO. Ultrasound characteristics of functional myocardial changes following the application of mesenchymal stem cell conditioned medium in an experimental autoimmune myocarditis model. Ukrainian J Cardiology. 2024;31(6):35-46. https://doi.org/10.31928/2664-4479-2024.6.3546
Maniewska J, Jeżewska D. Non-steroidal anti-inflammatory drugs in colorectal cancer chemoprevention. Cancers (Basel). 2021;13(4):594. https://doi.org/10.3390/cancers13040594
Eleiwa NZH, Khalifa HAMI, Nazim HA. Cardioprotective role of royal jelly in the prevention of celecoxib-mediated cardiotoxicity in adult male albino rats. J Cardiothoracic Surg. 2024;19(1):135. https://doi.org/10.1186/s13019-024-02593-2
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7. https://doi.org/10.1080/14653240600855905
Hladkykh F, Student V, Liadova T, Lykhatska H, Komorovsky R, Smiyan S. Conditioned medium of mesenchymal stem cells: dual anti-inflammatory and analgesic effects in rheumatoid arthritis model. Archives of the Balkan Medical Union. 2025;60(4):483-91. https://doi.org/10.31688/ABMU.2025.60.4.04
Ahmad S, Panda BP, Kohli K, Fahim M, Dubey K. Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. Pharmaceutical Biology. 2017;55(1):1295-303. https://doi.org/10.1080/13880209.2017.1299768
Jensen RA, Acton EM, Peters JH. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. J Cardiovasc Pharmacol. 1984;6(1):186-200.
Stefanov OV, ed. Preclinical studies of medicinal products. Methodological recommendations. Kyiv: Avicenna; 2001. 527 p.
Alanazi AM, Fadda L, Alhusaini A, Ahmad R, Hasan IH, Mahmoud AM. Liposomal resveratrol and/or carvedilol attenuate doxorubicin-induced cardiotoxicity by modulating inflammation, oxidative stress and S100A1 in rats. Antioxidants (Basel). 2020;9(2):159. https://doi.org/10.3390/antiox9020159
Hladkykh FV. Assessment of the effects of mesenchymal stem cell conditioned medium and cryoextracts of biological tissues on manifestations of cytolytic syndrome in experimental autoimmune hepatitis. Odesa Med J. 2024;6(191):45-50. https://doi.org/10.32782/2226-2008-2024-6-8
Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sciences. 1999;65(12):1265-74. https://doi.org/10.1016/S0024-3205(99)00362-8
Arozal W, Watanabe K, Veeraveedu PT, Ma M, Thandavarayan RA, Sukumaran V, et al. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology. 2010;274(1-3):18-26. https://doi.org/10.1016/j.tox.2010.05.003
Thoman CJ. The versatility of polysorbate 80 (Tween 80) as an ionophore. J Pharmaceutical Scie. 1999;88(2):258-60. https://doi.org/10.1021/js980216n
Chyzh MO, Manchenko AO, Trofimova AV, Belochkina IV. Ultrasound assessment of heart remodelling affected by therapeutic hypothermia and MSC on myocardial infarction model. Ukrainian J Radiology and Oncology. 2020;3(28):222-40. https://doi.org/10.46879/ukroj.3.2020.222-240
Chyzh MO, Belochkina IV, Globa VYu, Sleta IV, Mikhailova IP, Hladkykh FV. Ultrasound examination of rat hearts after experimental epinephrine-induced damage and the application of heart xenoextract. The Journal of V.N. Karazin Kharkiv National University. Series Medicine. 2024;32(2(49)):185-97. https://doi.org/10.26565/2313-6693-2024-49-06
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450-8. https://doi.org/10.1016/0002-9149(86)90771-x
Zhou Y, Zhu Y, Wong WK. Statistical tests for homogeneity of variance for clinical trials and recommendations. Contemporary Clinical Trials Communications. 2023;33:101119. https://doi.org/10.1016/j.conctc.2023.101119
Di Y, Zhao S, Fan H, Li W, Jiang G, Wang Y, Li C, Wang W, Wang J. Mass Production of Rg1-Loaded Small Extracellular Vesicles Using a 3D Bioreactor System for Enhanced Cardioprotective Efficacy of Doxorubicin-Induced Cardiotoxicity. Pharmaceutics. 2024;16(5):593. https://doi.org/10.3390/pharmaceutics16050593